Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi’s Sarcoma Cells*

Received for publication, June 26, 2003, and in revised form, November 18, 2003
Published, JBC Papers in Press, November 19, 2003, DOI 10.1074/jbc.M306824200

Stefano Buttiglieri, Maria Chiara Deregibus, Stefania Bravo, Paola Cassoni, Roberto Chiarello, Benedetta Bussolati, and Giovanni Camussi§

From the Cattedra di Nefrologia, Dipartimento di Medicina Interna and Centro Ricerca Medicina Sperimentale and Dipartimento di Scienze Biomediche e Oncologia, Università di Torino, Torino 10126, Italy

In this study, we found that Kaposi’s sarcoma cells but not human microvascular endothelial cells expressed Pax2, a gene coding for a transcription factor involved in organogenesis and tumorigenesis. Moreover, Pax2 was frequently expressed, on spindle-shaped cells, in Kaposi’s sarcoma lesions. We cloned Pax2 from Kaposi’s sarcoma cells and obtained antisense and sense DNA. Transfection of Kaposi’s sarcoma cells with antisense DNA, which suppressed Pax2 protein expression, reduced cell growth and survival and enhanced the sensitivity of Kaposi’s sarcoma cells to apoptosis induced by serum deprivation or vincristine treatment. In addition, antisense transfection inhibited the cell motility, the invasion of Matrigel, and the spindle shape morphology, which are characteristics of Kaposi’s sarcoma cells. Moreover, the αvβ3 integrin, known to be involved in tumor invasion, was down-regulated. To evaluate the possible role of Pax2 expression in the endothelial origin of Kaposi’s sarcoma cells, human microvascular endothelial cells were transfected with sense DNA. Endothelial cells transfected with sense Pax2 acquired spindle shape morphology, showed enhanced motility and Matrigel invasion, and displayed an enhanced expression of αvβ3 integrin. In conclusion, the expression of Pax2 by Kaposi’s sarcoma cells correlated with an enhanced resistance against apoptotic signals and with the proinvasive phenotype. Moreover, Pax2-transfected endothelial cells acquired a phenotype resembling that of Kaposi’s lesional cells, suggesting a role of this embryonic gene in tumorigenesis.

Kaposi’s sarcoma (KS) is an angiogenic tumor containing spindle-shaped cells, fibroblasts, inflammatory cells, and vascular endothelial and smooth muscle cells (1–3). KS is frequently associated with conditions of immunodysregulation such as that occurring in HIV-1 infection and long term post-transplantation therapy (4). The growth and diffusion of KS has been ascribed not only to a dysregulation of cellular proliferation but also to a resistance against apoptotic signals derived from the activation of endogenous or exogenous execution death program. Several factors may contribute to resistance to apoptosis, including a dysregulation of the cytokine network, which has been implicated in the pathogenesis of KS (5), and the effect of HIV-derived proteins such as Tat (6). Recently, we found that HIV-1 Tat acts as survival factor for KS cells (7) by a mechanism involving a phosphatidylinositol 3-kinase/Akt-dependent pathway (8). In preliminary experiments, we observed by gene array technology that KS cells express in basal conditions several antiapoptotic genes (8).

It has been recently reported that paired box gene 2 (PAX2) expression suppresses apoptosis in renal collecting duct cells (9). Pax2 protein is a transcription factor belonging to the evolutionary conserved paired box family involved in organogenesis. Pax2 is required for development of the central nervous system and genitourinary tract. In humans, Pax2 is expressed in induced mesenchyme and in the early epithelial derivatives, and it is rapidly down-regulated in mature kidney (10). The expression of Pax2 was observed in renal cell carcinomas (11) and in mammary tumors (12). A possible role of Pax2 expression in tumor growth has been suggested by using antisense oligonucleotide in renal carcinoma cells (11).

The aim of the present study was to evaluate whether KS cells express Pax2 and whether its expression influences KS cell behavior. For this purpose, KS cells were transfected with the antisense PAX2 gene to inhibit Pax2 protein expression, and the resistance to apoptosis as well as the growth, the motility and the invasion of Matrigel were evaluated. Moreover, to study the possible role of Pax2 expression in the endothelial origin of Kaposi’s sarcoma cells, human microvascular endothelial cells (HMEC) were transfected with sense DNA.

EXPERIMENTAL PROCEDURES

Reagents—Endothelial cell attachment factor, DMEM, and bovine serum albumin fraction V (tested for not more than 1 ng of endotoxin per mg) were purchased from Sigma. Modified MCDB131 medium was obtained from Invitrogen, and fetal calf serum (FCS) was from EuroClone Ltd. (Wetherby, West Yorkshire, UK). Polyclonal rabbit antibody (Ab) against Pax2 was purchased from Covance (Princeton, NJ). Anti-αvβ3 mAbs were from Chemicon Int. (Temecula, CA); fluorescein isothiocyanate (FITC)-labeled anti-platelet endothelial cell adhesion molecule mAb was from Euroclone; anti-ICAM-1, anti-CD11α, and anti-CD11β mAbs were from BD Bioscience; and anti-E-selectin mAb was from Serotec (Raleigh, NC). Anti-αv and anti-β3 mAbs were kindly provided by Guido Tarone (University of Torino, Italy). Vincristine and geneticin were obtained from Sigma.

Detection of Pax2 in KS Lesions by Immunohistochemistry—Surgical sample from eight patients (age range, 49–77 years; sex, 4 male and 4 female) were processed and stained as described above.
female patients) with KS were collected. Five were classical cutaneous KS lesions, two were visceral KS (one gastric and one lung primary localization), and one was a lymph node metastasis in a patient with visceral iatrogenic KS. The different cell types were characterized using either morphological criteria or immunohistochemistry with Abs directed toward cell-specific antigens (such as CD31 for spindle cells or factor VIII for vessels) (13). Serial sections from representative paraffin-embedded blocks of human KS lesions were collected onto poly-lysine-coated slides and stained for PAX2 antigen. Endogenous peroxidase activity was blocked with 6% H2O2 for 5 min at room temperature. Anti-PAX2 Ab was diluted 1:150 in phosphate-buffered saline (PBS) (pH 7.4) and applied to slides overnight at room temperature. Biotin-labeled goat anti-rabbit serum diluted 1:2000 (Sigma) was incubated for 30 min followed by the streptavidin peroxidase LSAB2 method (Dakopatts, Glostrup, Denmark) for the second Ab reaction. The reaction product was developed using 3,3′-diaminobenzidine. Omission of the primary Ab or substitution with an unrelated rabbit serum served as negative control.

**Cell Cultures—** Four Kaposi's sarcoma cell lines were used: three primary cultures of Kaposi's sarcoma cells (KS cells, KS-C1, and KS-L3) (7, 8) and a spontaneously immortalized cell line (KS-imm) (14). These cell lines were previously characterized (7) in comparison with a well-characterized KS cell line (SLK) developed by Herndier et al. (39). Cells were cultured with DMEM (Sigma) containing 10% FCS and 2 mM glutamine (Sigma). HMEC were obtained from derma using anti-CD31 Ab coupled to magnetic beads, by magnetic cell sorting using the MACS system (Miltenyi Biotec, Auburn, CA), and immortalized by infection of primary cultures with a replication-defective adenovirus (55/SV40 virus as previously described (15)). Two primary microvascular endothelial cell lines obtained from subcutaneous fat and three umbilical cord vein-derived endothelial cell lines (HUVEC) were prepared as previously described (16). Endothelial cells were characterized as endothelial cells by morphology and positive staining for von Willebrand factor antigen and for CD31, CD105, and the fucosylated receptors for plant lectins (Ulex europeus I and Bandeiraea simplicifolia). Cytoplasmatic staining was positive for vimentin and negative for cytokeratin and desmin, as previously described (17). A previously characterized renal carcinoma cell line (K1) was used as positive control for PAX2 expression (18).

**Cloning of PAX2 Gene—** Total RNA was extracted from KS cells with guanidinium thiocyanate/phenol/chloroform, precipitated with isopropl alcohol, and washed with 70% ethanol. Two micrograms of RNA were retrotranscribed using oligo(dT) primers and 15 units of reverse transcriptase (RT) enzyme (Eppendorf, Hamburg, Germany). Five microliters of cDNA were amplified with forward and reverse primers (forward, ATGGATATGAAGTCAGCAGCAAGCAGCA; reverse, CTAGTGGCAGTCTAGAGGCAAG) covering the initial and terminal part of the coding sequence, respectively (NCBI GenBank number GI409138), with Taq DNA polymerase (Invitrogen). Amplified DNA was ligated in pTARGET mammalian expression vector (Promega, Madison, WI) under the control of the cytomegalovirus promoter with the T/A cloning system. After sequencing various clones, we identified a clone with PAX2 in correct orientation (S) and a clone with PAX2 in inverse orientation (AS). DNA sequence was compared with the NCBI data base using the BLAST program.

**Transfection—** Cells were seeded in a 10-cm Petri dish to reach confluence and transfected with 8 µg of DNA and 20 µl of LipofectAMINE 2000 (Invitrogen) in DMEM containing 10% FCS without antibiotics, according to the protocol suggested by the manufacturer. As a control, cells were transfected with the empty plasmid (KS Ctrl). Transfected cells were stably selected by culturing in the presence of 1 mg/ml geneticin. Successful transfection was evaluated by positive immunofluorescence for anti-PAX2 Ab.

**Western Blot Analysis—** Cells were lysed at 4°C for 1 h in a lysis buffer (50 mM Tris-HCl, pH 8.3, containing 1% Triton X-100, 10 mM phenethylsulfonyl fluoride, 10 mM leupeptin, and 100 units/ml aprotinin) and centrifuged at 15,000 × g. The protein contents of the supernatants were measured by the Bradford method. Aliquots containing 10 µg of protein of the cell lysates were subjected to SDS-10% PAGE under reducing conditions and blotted onto nitrocellulose membrane filters. The blots were blocked with 5% nonfat milk in 20 mM Tris-HCl, pH 7.5, 500 mM NaCl plus 0.1% Tween (TBS-T). The membranes were subsequently immunoblotted overnight at 4°C with the rabbit anti-PAX2 Ab. After extensive washing with TBS-T, the blots were incubated for 1 h at room temperature with peroxidase-conjugated anti-rabbit IgG (Pierce), washed with TBS-T, developed with ECL detection reagents (Amer sham Biosciences) for 1 min, and exposed to X-Omat film (Eastman Kodak Co.).

**RT-PCR—** Total RNA was extracted from cells with guanidinium thiocyanate/phenol/chloroform, precipitated with isopropl alcohol, and washed with 70% ethanol. Two micrograms of RNA were retrotranscribed using oligo(dT) primers and 15 units of RT enzyme (Eppendorf). Two microliters of cDNA were amplified with forward (ATGGATATGACAGCAGCA) and reverse (CTAGTGGCAGTCTAGAGGCA) primers, with Taq DNA polymerase (Invitrogen). Reactions were performed for 30 cycles at a melting temperature of 52°C and analyzed with a BrTOH 1.5% agarose gel.

**Cell Proliferation Assay—** Cells were seeded at 8,000 cells/well into 96-well plates in DMEM containing 10% FCS and allowed to adhere. DNA synthesis was detected as incorporation of 5-bromo-2'-deoxyuridine (BrdUrd) into the cellular DNA using an enzyme-linked immunosorbent assay kit (Roche Applied Science), following the manufacturer’s instructions. Briefly, after washing, cells were added with 10 µM BrdUrd and incubated in DMEM without FCS or in DMEM plus 10% FCS for 18 h. Cells were then fixed with 0.5% ethanol/HCl and incubated with nuclease to digest the DNA. BrdUrd incorporated into the DNA was detected using an anti-BrdUrd peroxidase-conjugated mAb and visualized with a soluble chromogenic substrate. Optical density was measured with an enzyme-linked immunosorbent assay reader at 405 nm.

**Cell Cycle Analysis—** Cells were seeded on 6-well plates in the presence or in absence of serum and analyzed after a 24-h incubation at 37°C. Cells were trypsinized, washed in PBS, and incubated for 1 h at 4°C in 1 ml of hypotonic solution containing 50 µg/ml propidium iodide, 0.1% sodium citrate, 0.1% Triton X-100, and 20 µg/ml DNase-free RNase A. Cells were analyzed with flow cytometry in linear mode. Results were expressed as percentages of elements detected in the
**RESULTS**

The expression of Pax2 protein was evaluated by Western blot analysis on four Kaposi's cell lines, on immortalized HMEC, on two primary microvascular endothelial cell lines, on three HuVEC lines, and on K1 renal carcinoma cells used as a positive control. As shown in Fig. 1A, KS cells, KS-imm, and KS-C1 as well as K1 renal carcinoma cells strongly expressed Pax2 protein. The expression of Pax2 protein by KS-L3 was minimal. In contrast, all of the different endothelial cell lines were negative. The expression of Pax2 mRNA from KS cells was confirmed by RT-PCR (Fig. 1B). To evaluate the *in vivo* expression of Pax2 in Kaposi's sarcoma, immunohistochemical analysis was performed on five classical cutaneous and two visceral KS lesions and on lymph node metastases. The results obtained indicate that three cutaneous and two noncutaneous lesions (the gastric KS localization and the lymph node metastases) were positive for Pax2 expression on fusate spindle-shaped lesional cells (Fig. 1C), whereas vessels where negative.

To study the possible relevance of Pax2 expression, the proliferation of Pax2 protein. The expression of Pax2 by the KS cells was analyzed by an immunofluorescence assay system (Cast Imaging). The figure shows a significant reduction in proliferation in cells transfected with *PAX2* antisense. Proliferation was, conversely, significantly enhanced in Pax2-transfected HMEC. Results are expressed as mean ± S.D. of eight experiments. Analysis of variance with Dunnett's multi-comparison test was performed versus control. *, *p* < 0.005; ***, *p* < 0.001.

**Immunofluorescence and Cytoluminometric Analysis**—Cultured cells were grown in 10 cm dishes, fixed with 4% paraformaldehyde in PBS, and permeabilized with 0.2% Triton X-100. Cells were blocked with 1% bovine serum albumin in PBS for 1 h at room temperature. To reduce nonspecific binding, cells were stained by the addition of FITC-conjugated goat anti-rabbit IgG Ab (Dako, Copenhagen, Denmark) and visualized on a Leica microscope with fluorescence optics.

**Assessment of Apoptosis**—Apoptosis was evaluated using the TUNEL assay. The percentage of TUNEL-positive cells was scored on random fields of 1000 nuclei per sample.

**Activation of Caspase-3 and -9 Activity**—Activation of caspase-3 and -9 was assessed by a colorimetric assay (Chemicon International) based on spectrophotometric detection of the chromophore p-nitroanilide (pNA) after cleavage from the labeled substrate DEVD-pNA, which is recognized by caspase-3, and LEHD-pNA, which is recognized by caspase-9. Lysates of treated or untreated cells were diluted 1:1 with 2% reaction buffer (10 mM Tris [pH 7.4], 1 mM dithiothreitol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.1% (3-(3-cholamido propane)sulfonyl) propyl(dimethylammonio)-1-propanesulfonate, pepstatin (10 μg/ml), and leupeptin (10 μg/ml)). DEVD-pNA or LEHD-pNA was added at a final concentration of 50 μM, and the reaction was incubated for 1 h at 37 °C. The absorption values were measured at 405 nm in an enzyme-linked immunosorbent assay reader.

**In Vitro Cell Migration**—A total of 1 × 10^4 cells/well was plated in DMEM containing 10% FCS. Cell migration was studied over a 4-h period under a Nikon Diaphot inverted microscope with a ×20 phase-contrast objective in an attached, hermetically sealed Plexiglas Nikon NA, which is recognized by pNA after cleavage from the labeled substrate DEVD-pNA.

**Detection of Caspase-3 and -9 Activity**—Activation of caspase-3 and -9 was assessed by a colorimetric assay (Chemicon International) based on spectrophotometric detection of the chromophore p-nitroanilide (pNA) after cleavage from the labeled substrate DEVD-pNA, which is recognized by caspase-3, and LEHD-pNA, which is recognized by caspase-9. Lysates of treated or untreated cells were diluted 1:1 with 2% reaction buffer (10 mM Tris [pH 7.4], 1 mM dithiothreitol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.1% (3-(3-cholamido propane)sulfonyl) propyl(dimethylammonio)-1-propanesulfonate, pepstatin (10 μg/ml), and leupeptin (10 μg/ml)). DEVD-pNA or LEHD-pNA was added at a final concentration of 50 μM, and the reaction was incubated for 1 h at 37 °C. The absorption values were measured at 405 nm in an enzyme-linked immunosorbent assay reader.

**Scanning Electron Microscopy**—Cells were fixed in Karnowsky—s fixative for 1 h, dehydrated in alcohol, dried, and coated with gold by sputter coating and examined in a scanning electron microscope (Jeol JSM T300) operating at 25 kV.
pTARGET mammalian expression vector under the control of cytomegalovirus promoter with the T/A cloning system. After sequencing various clones, we identified a clone with \( \text{PAX2} \) in correct orientation (S) and a clone with \( \text{PAX2} \) in inverse orientation (AS). KS cells were stably transfected with \( \text{PAX2} \) in inverse orientation (KS-AS), and the Pax2 protein expression was evaluated. As shown in Fig. 2, the immunofluorescence staining of Pax2 was markedly reduced in KS-AS (Fig. 2B) with respect to KS-Ctrl transfected with the empty vector (Fig. 2A).

The reduced expression of Pax2 protein in KS-AS cells was confirmed by Western blot analysis (Fig. 2E). HMEC, which express a minimal amount of Pax2 protein (Fig. 2C), were conversely transfected with the vector containing sense DNA (HMEC-S) in order to obtain expression of Pax2 (Fig. 2D).

As shown in Fig. 3, the growth of KS-AS cells was significantly reduced both in the presence or in the absence of FCS with respect to KS-Ctrl. Transfection of HMEC with sense \( \text{PAX2} \) significantly enhanced cell BrdUrd uptake.

Cell cycle analysis showed a significant reduction of \( G_2/M \) and S peaks in KS-AS with respect to KS-Ctrl (Fig. 4). In addition, a marked increase in sub-\( G_1 \) peak was observed both in the presence or absence of FCS, suggesting an enhanced apoptosis in cells transfected with \( \text{PAX2} \) antisense.

An enhanced sensitivity to apoptosis of KS-AS cells with respect to KS-Ctrl was also detected by a TUNEL assay (Fig. 5A). This was already detectable in the presence of FCS and markedly enhanced after serum starvation and vincristine treatment. The antiapoptotic effect of Pax2 was confirmed by the observation that HMEC-S were significantly more resistant to apoptosis induced both by serum deprivation and vincristine with respect to HMEC-Ctrl. The increased sensitivity of KS-AS to apoptosis was also indicated by the enhanced activation of caspase-9 and -3 after serum deprivation and vincristine treatment (Fig. 5, B and C).

The basal motility of KS cells detected by time lapse cinematography was significantly decreased in KS-AS with respect to KS-Ctrl (Fig. 6, A–C). Conversely, transfection of HMEC with \( \text{PAX2} \) sense DNA significantly enhanced cell motility with respect to HMEC-Ctrl (Fig. 6, A, D, and E).

The \textit{in vitro} invasive property in Matrigel and the spindle shape morphology are considered characteristic features of KS lesional cells (20–24). We therefore evaluated the effect of Pax2 expression on these properties. As shown in Fig. 7, invasiveness of Matrigel by KS-AS was significantly reduced with respect to KS-Ctrl, whereas invasiveness of Matrigel by HMEC-S was significantly enhanced with respect to HMEC-Ctrl. Moreover, KS-AS lost the characteristic spindle shape morphology observed in KS-Ctrl (Fig. 8, A–D). In analogy to this result, HMEC-S tended to develop a spindle shape resembling that of KS cells (Fig. 8, E–H).

To investigate the potential mechanism by which Pax2 may regulate the invasive phenotype, we studied the effect of trans-
In the present study, we demonstrated that KS cells express Pax2 and that its expression contributes to resistance to apoptosis and the proinvasive phenotype of KS cells. Aside from dysregulation of cellular proliferation, the resistance to apoptotic signals has been implicated in the pathogenesis of KS. Indeed, KS cells, despite the expression of Fas on their surface, were shown to be resistant to Fas-mediated apo-

**DISCUSSION**

In the present study, we demonstrated that KS cells express Pax2 and that its expression contributes to resistance to apoptosis and the proinvasive phenotype of KS cells.

Aside from dysregulation of cellular proliferation, the resistance to apoptotic signals has been implicated in the pathogenesis of KS. Indeed, KS cells, despite the expression of Fas on their surface, were shown to be resistant to Fas-mediated apo-
PAX2, a gene coding for a transcription factor belonging to the evolutionary conserved paired box family involved in organogenesis (27), has been recently shown to protect renal collecting duct cells from apoptosis. Moreover, it has been shown that expression of Pax2 in renal cells was shown to protect these cells against apoptotic death induced by caspase 2 (9). In the present study, we observed by TUNEL assay that transfection with antisense DNA significantly increased the number of apoptotic KS cells in basal conditions and enhanced the sensitivity of KS cells to apoptosis induced by serum deprivation or vincristine treatment. The observation that transfection of KS cells and HMEC with the PAX2 antisense or sense vectors, KS-Ctrl showed characteristics spindle cell morphology by phase-contrast (A) and scanning electron microscopy (B). KS-AS showed the loss of spindle shape morphology after transfection with PAX2 antisense by phase-contrast (C) and scanning electron microscopy (D). HMEC-Ctrl showed the characteristic cobblestone-like appearance by phase-contrast (E) and a very flattened appearance with nuclei and nucleoli protruding from the even surface by scanning electron microscopy (F). After transfection with PAX2 sense vector, HMEC-S tended to lose contact with neighbor cells and developed a spindle shape morphology (G and H). A, C, E, and G, magnification was ×250; B, D, F, and H, magnification was ×1000. Three different experiments were performed with similar results.

Fig. 6. Effect of transfection of KS cells and HMEC with the PAX2 antisense or sense vectors on in vitro cell migration. Motility was performed by digital saving at 15-min intervals over a 4-h period of cells incubated at 37°C with 10% FCS. A shows means ± S.D. of three independent experiments. B–E show representative micrographs of the time lapse analysis of KS-AS (B), KS-Ctrl (C), HMEC-S (D), and HMEC-Ctrl (E). Migration tracks (magnification, ×120) were generated by marking the position of the nucleus of individual cells in each image (see “Experimental Procedures”).

Fig. 7. Effect of transfection of KS cells and HMEC with the PAX2 antisense or sense vectors on the in vitro Matrigel invasion assay. The matrix invasion assay was performed by seeding 10⁵ cells on the upper side of porous polycarbonate membrane of 8-μm pore size coated with 12.5 μg of Matrigel. Cells migrated through the membrane at the lower side of the filter were counted in the lower side of the transwells after incubation of KS-Ctrl and KS-AS for 24 h and of HMEC-Ctrl and HMEC-S for 72 h. Results are expressed as a percentage of migrated cells with respect to total cells seeded. Data are the mean ± S.D. of three different experiments.

Fig. 8. Micrographs representative of the morphological changes induced by transfection of KS cells and HMEC with the PAX2 antisense or sense vectors. KS-Ctrl showed characteristics spindle cell morphology by phase-contrast (A) and scanning electron microscopy (B). KS-AS showed the loss of spindle shape morphology after transfection with PAX2 antisense by phase-contrast (C) and scanning electron microscopy (D). HMEC-Ctrl showed the characteristic cobblestone-like appearance by phase-contrast (E) and a very flattened appearance with nuclei and nucleoli protruding from the even surface by scanning electron microscopy (F). After transfection with PAX2 sense vector, HMEC-S tended to lose contact with neighbor cells and developed a spindle shape morphology (G and H). A, C, E, and G, magnification was ×250; B, D, F, and H, magnification was ×1000. Three different experiments were performed with similar results.

Pax2 Suppresses Apoptosis in Kaposi’s Sarcoma Cells

Pax2 is frequently expressed in KS lesional cells suggesting its possible involvement in the cancer pathogenesis (10, 11, 28). In the present study, we found that several Kaposi’s sarcoma cell lines markedly expressed both Pax2 mRNA and Pax2 protein. The immunohistochemical analysis of classical cutaneous and visceral and lymphatic KS lesions suggests that Pax2 is frequently expressed in KS lesional cells in vivo. However, the expression of Pax2 was not detected in all tumors, and in positive tumors only a variable fraction of tumor cells expressed this protein. This is consistent with immunohistochemical studies on other primary tumors, suggesting that Pax2 gene function is required only at certain stages of tumor cell development (28).

These results prompted us to evaluate whether Pax2 expression plays a role in the KS tumorigenesis. A previous study demonstrated that when renal carcinoma cells expressing high levels of Pax2 were treated with antisense Pax2 oligonucleotides, in vitro, cell number was dramatically reduced (11). In the present study, Pax2 was cloned from KS cells, and antisense and sense DNA were obtained. Transfection of KS cells with antisense DNA inhibited incorporation of BrdUrd, suggesting a reduced growth. The analysis of the cell cycle evidenced a significant difference in the S or G2/M phases between KS-AS and control cells transfected with the empty vector. Moreover, cells in the hypodiploid phase (sub-G1 peak) were significantly increased in KS-AS, suggesting that transfection with PAX2 antisense had a major effect on apoptosis. It has been recently shown that high levels of Pax2 protein were necessary for survival of renal collecting duct cells and optimal branching morphogenesis during renal development. Expression of Pax2 in renal cells was shown to protect these cells against apoptotic death induced by caspase 2 (9). In the present study, we observed by TUNEL assay that transfection with PAX2 antisense DNA significantly increased the number of apoptotic KS cells in basal conditions and enhanced the sensitivity of KS cells to apoptosis induced by serum deprivation or vincristine treatment. The observation that transfection of HMEC with sense PAX2 DNA conferred resistance to apoptosis and to a minor extent stimulated proliferation confirms that Pax2 primary function is antiapoptotic. An association has
been reported between apoptosis and other members of the paired box gene families (9). Pax3 mutant mice exhibited increased apoptosis of somatic mesoderma (29). Pax2, Pax5, and Pax8 all inhibit transcription of p53, a pivotal molecule regulating the final common apoptotic pathway (30, 31). In addition, Pax6 mutation has been shown to correlate with excessive apoptosis of photoreceptor precursor (32).

The possible relevance of Pax2 expression to pathogenesis of KS is also supported by the inhibitory effect of antisense transfection on cell motility, invasion of Matrigel, and spindle shape morphology, which are characteristics of KS cells. The figure is representative of three different experiments. Kolmogorov-Smirnov statistical analysis between transfected and control cells was performed in each individual experiment.

Fig. 9. Effect of transfection of KS cells with PAX2 antisense and of HMEC with PAX2 sense on adhesion molecules. A shows the $\alpha_\beta_3$ dimer expression in KS-Ctrl (dark line; 82 ± 3% of cells) and in KS-AS (gray line; 14 ± 2% of cells). B shows the $\alpha_\beta_3$ dimer expression in HMEC-Ctrl (gray line; 12 ± 3% of cells) and in HMEC-S (dark line; 63 ± 5% of cells). $\alpha_\beta_3$ dimer was significantly down-regulated in KS-AS and up-regulated in HMEC-S in comparison with the respective controls. The filled area shows the isotype controls. The figure is representative of three different experiments. Kolmogorov-Smirnov statistical analysis between transfected and control cells was performed in each individual experiment.

In humans, the oncogenic potential of Pax2 remains to be determined. In mice, it has been shown that the induction of tumor formation was dependent on the type of paired domain but did not require the presence of homeodomain. It has been suggested that the oncogenic potential of Pax proteins is dependent on the DNA-binding function of the paired motif. Therefore, not only the Pax3 and Pax6 proteins containing intact homeodomain, but also Pax2 and Pax8 containing residual homeodomain and Pax1, completely lacking a homeodomain, were able to induce transformation of cell culture and tumor formation in mice (38).

In the present study, the expression of Pax2 by KS cells correlated with enhanced resistance against apoptotic signals derived from activation of endogenous execution programs and exogenous stimuli and with the proinvasive phenotypes of KS cells.

Altogether, these results suggest that Pax gene products are not only involved in controlling embryogenesis, but, if deregulated, they can also induce tumorigenesis.
REFERENCES

1. Ensoli, B., Barillari, G., Salahuddin, S. Z., Gallo, R. C., and Wong-Staal, F. (1990) Nature 345, 84–86
2. Gallo, R. C. (1998) Science 282, 1837–1839
3. Rabkin, C. S., Janz, S., Lash, A., Coleman, A. E., Musaba, E., Lotta, L., Biggar, R. J., and Zhuang, Z. (1997) N. Engl. J. Med. 336, 988–993
4. Mitsuya, H. T. (2000) Curr. Opin. Oncol. 12, 174–180
5. McCloskey, T. W., Ott, M., Tribble, E., Khan, S. A., Teichberg, S., Paul, M. O., and McEwan, R. N. (1997) J. Infect. Dis. 175, 833–839
6. Albini, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaroson, S. A., and Albini A., and Camussi, G. (2002) Cancer Res. 62, 55, 693–699
7. Rabkin, C. S., Janz, S., Lash, A., Coleman, A. E., Musaba, E., Lotta, L., Biggar, R. J., and Zhuang, Z. (1997) N. Engl. J. Med. 336, 988–993
8. Deregibus, M. C., Cantaluppi, V., Doublier, S., Brizzi, M. F., Deambrosis, I., Albinz, A., and Camussi, G. (2005) J. Biol. Chem. 280, 1014–1019
9. Becksted, J. H., Woods, G. S., and Fletcher, V. (1985) Am. J. Pathol. 119, 294–300
10. Corbeil, J., Evans, L. A., Vasak, E., Cooper, D. A., and Penney, R. (1991) J. Immunol. 146, 2972–2976
11. J., Evans, L. A., Vasak, E., Cooper, D. A., and Penney, R. (1991) J. Immunol. 146, 2972–2976
12. Mussula, L., Valtola, R., Partanen, T. A., Salonen, P., Heikhi, P., Matikainen, M. T., Rinkonen, R., Kalpainen, A., Petäinen, M., Tschachler, E., Alitalo, R., and Alitalo, K. (1998) Cancer Res. 58, 1599–1604
13. Salamuddin, S. Z., Nakamura, S., Biberfeld, P., Kaplan, M. H., Markham, P. D., Arsson, L., and Gallo, R. C. (1998) Science 242, 430–433
14. Scully, P. A., Steinman, H. K., Kennedy, C., Trueblood, K., Frisman, D. M., and Voland, J. R. (1998) Am. J. Pathol. 130, 244–251
15. Mori, S., Murakami-Mori, K., Jewett, A., Nakamura, S., and Bonavida, B. (1998) Cancer Res. 58, 1874–1879
16. Lee, F. C., and Mitsuya, R. T. (1996) Hematol. Oncol. Clin. North Am. 10, 1051
17. Dahl, E., Koseki, H., and Balling, R. (1997) BioEssays 19, 755–765
18. Muratovska, A., Zhou C., He, S., Goodyer, P., and Eccles, M. R. (2003) Oncogene 22, 6054–6053
19. Boryczka, A. G., Li, J., Emerson, C. P., Jr., and Epstein, J. A. (1999) Development 126, 1665–1674
20. Stuart, E. T., Haffner, R., Oren, M., and Gruss, P. (1995) EMBO J. 14, 5638–5645
21. Levine, A. J. (1997) Cell 8, 323–331
22. Halder, G., Callaerts, P., Flister, S., Walldorf, U., Kloter, U., and Gering, W. J. (1998) Development 125, 2181–2191
23. Ploegh, O., Rafi, S., Ely, S., O’Leary, J. J., Hylak, E. M., and Cesareman, E. (1998) Nature 394, 588–592
24. Moses, A. V., Fish, K. N., Ruhl, R., Smith, P. P., Strussergen, J. G., Zhu, L., Chandran, B., and Nelson, J. A. (1999) J. Virol. 73, 6892–6892
25. Ensoli, B., Gentelman, R., Markham, P., Fiorello, V., Colomboni, S., Raffeld, M., Cafaro, A., Chang, H. K., Brady, J. N., and Gallo, R. C. (1994) Nature 371, 674–680
26. Uccini, S., Ruiz, L. P., Monardo, F., Stoppanicario, A., Dejana, E., Parolla, I. L., Cerimele, D., and Baroni, C. D. (1994) J. Pathol. 173, 23–31
27. Kaaya, E. E., Castanos-Velez, E., Amir, H., Lema, L., Luande, J., Kitinya, J., Patarryo, M., and Biberfeld, P. (1996) Histopathology 29, 337–346
28. Maulbecker, C. C., and Gruss, P. (1993) EMBO J. 12, 2361–2367
29. Herndier, B., Werner, A., and Arnstein, P. (1994) AIDS 8, 575–581

Pax2 Suppresses Apoptosis in Kaposi’s Sarcoma Cells
Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells
Stefano Buttiglieri, Maria Chiara Deregibus, Stefania Bravo, Paola Cassoni, Roberto Chiarle, Benedetta Bussolati and Giovanni Camussi

J. Biol. Chem. 2004, 279:4136-4143.
doi: 10.1074/jbc.M306824200 originally published online November 19, 2003

Access the most updated version of this article at doi: 10.1074/jbc.M306824200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 39 references, 13 of which can be accessed free at
http://www.jbc.org/content/279/6/4136.full.html#ref-list-1